Liu et al. isolated 50 escape mutants to 19 monoclonal antibodies targeting the SARS-CoV-2 spike using a VSV-SARS2 chimera. Some mutants (S477N) resist neutralization by multiple mAbs, and others (E484K) are less sensitive to neutralization by convalescent sera. Several mutants exist in clinical SARS2-CoV-2 isolates and thus warrant further study.

Original languageEnglish
Pages (from-to)477-488.e4
JournalCell Host and Microbe
Issue number3
StatePublished - Mar 10 2021


  • ACE2 receptor decoys
  • COVID-19 vaccines
  • SARS-CoV-2 escape mutants
  • convalescent sera
  • coronaviruses
  • monoclonal antibodies
  • receptor-binding domain


Dive into the research topics of 'Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization'. Together they form a unique fingerprint.

Cite this